SAB-142 Shows Early C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial

Event summary

  • SAB Biotherapeutics' SAB-142 demonstrated early signals of C-peptide preservation in a Phase 1 trial for adult patients with established autoimmune Type 1 Diabetes.
  • Four patients treated with SAB-142 showed no decrease in C-peptide levels at Day 120, while the placebo participant exhibited a decline.
  • The Phase 1 HUMAN trial included six adult participants, with four receiving SAB-142 and two receiving placebo.
  • SAB-142 is advancing to the Phase 2b SAFEGUARD trial, with topline data expected in the second half of 2027.

The big picture

SAB Biotherapeutics' SAB-142 represents a novel approach to treating Type 1 Diabetes by preserving beta cell function. The early Phase 1 data suggests potential for disease modification, a significant shift from current management strategies focused on symptom control. The advancement to the Phase 2b SAFEGUARD trial marks a critical step in validating this therapeutic approach, with broader implications for the autoimmune disease treatment landscape.

What we're watching

Clinical Efficacy
Whether SAB-142 can sustain C-peptide preservation in larger, more diverse patient populations.
Regulatory Pathway
The pace at which SAB-142 advances through the SAFEGUARD trial and potential regulatory approval.
Market Positioning
How SAB-142 differentiates itself from existing treatments for Type 1 Diabetes.